A blueprint for better cancer immunotherapies
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
A newly characterized anti-viral defense system in bacteria aborts infection through a novel mechanism by chemically altering mRNA.
Study reveals the drug, 5-fluorouracil, acts differently in different types of cancer — a finding that could help researchers design better drug combinations.
The scientists, who worked together as postdocs at MIT, are honored for their discovery of microRNA — a class of molecules that are critical for gene regulation.
MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.
Genomics and lab studies reveal numerous findings, including a key role for Reelin amid neuronal vulnerability, and for choline and antioxidants in sustaining cognition.
Custom plates display expressions of scholarship, creativity, and MIT pride among Institute affiliates.
By capturing short-lived RNA molecules, scientists can map relationships between genes and the regulatory elements that control them.
SMART researchers find a cellular process called transfer ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Albert Almada PhD ’13 studies the mechanics of how stem cells rebuild tissues. “Digging deep into the science is what MIT taught me,” he says.
Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.
MIT researchers can now track a cell’s RNA expression to investigate long-term processes like cancer progression or embryonic development.
MIT researchers find that in mice and human cell cultures, lipid nanoparticles can deliver a potential therapy for inflammation in the brain, a prominent symptom in Alzheimer’s.